Drug therapy for obesity in the elderly

Drugs and Aging

Volumn 11, Issue 5, 1997, Pages 338-351

  Dvorak, Roman ^a   Starling, Raymond D ^a   Callés Escandon, Jorge ^a   Siins, Ethan A H ^a   Poehlmann, Eric T ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID METHYL ESTER HYDROGEN MALEATE; ANABOLIC AGENT; ANOREXIGENIC AGENT; BENZPHETAMINE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; CHROMIUM PICOLINATE; CL 346216; CYPROHEPTADINE; DEXFENFLURAMINE; EPHEDRINE; FENFLURAMINE; MAZINDOL; OXANDROLONE; PHENDIMETRAZINE; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; SEROTONIN AGONIST; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

AGED; BODY COMPOSITION; CALORIC INTAKE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATECHOLAMINERGIC SYSTEM; CLINICAL TRIAL; DIARRHEA; DROWSINESS; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; ENERGY EXPENDITURE; FATIGUE; FLATULENCE; HEART RATE VARIABILITY; HUMAN; HUNGER; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POLYURIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SATIETY; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0030780580     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199711050-00002     Document Type: Review

References (73)

1. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among adults. JAMA 1994; 272: 205-11
2. Kumanyika SK. Obesity in minority populations: an epidemiologic assessment. Obes Res 1994; 2: 166-82
3. Wolf AM, Colditz GA. Social and economic effects of body weight in the United States. Am J Clin Nutr 1996; 63 Suppl.: 466S-9S
4. Montague A. Obesity and the evolution of man. JAMA 1966; 195: 105-7
5. Bray GA. Obesity: historical development of scientific and cultural ideas. In: Björntorp P, Brodoff BN, editors. Obesity. New York: J.B. Lippincott Co., 1992: 281-93
6. Bray GA, Ryan DH. Drugs used in the treatment of obesity. Diabetes Metab Rev 1997; 5: 83-103
7. Guyton AC. Textbook of medical physiology. 8th ed. Philadelphia: W.B. Saunders Co., 1991: 779-82
8. Ganong WF. Review of medical physiology. 15th ed. East Norwalk (CT): Prentice Hall, 1992: 218-22
9. Read NW. Role of gastrointestinal tract in hunger and satiety in men. Proc Nutr Soc 1992; 51: 7-11
10. Read NW, French S, Cunningham K. The role of gut in regulating food intake in man. Nutr Rev 1994; 52: 1-10
11. Philips PA, Rolls BJ, Ledingham JGG, et al. Reduced thirst after water deprivation in healthy elderly. N Engl J Med 1984; 311: 753-9
12. Fischer J, Johnson MA. Low body weight and weight loss in the aged. J Am Diet Assoc 1990; 90: 1697-706
13. Silver AJ, Morley JE, Strome LS, et al. Nutritional status in the academic nursing home. J Am Geriatr Soc 1988; 36: 487-91
14. Poehlman ET. Energy intake and expenditure in the elderly. Am J Human Biol 1996; 8: 199-206
15. Leaf A. Dehydration in the elderly. N Engl J Med 1984; 311: 791-2
16. Shepherd AMM. Physiological changes with aging: relevance to drug study design. In: Cutler NR, Narang PK, editors. Drug studies in the elderly. New York: Plenum Publishing, 1986: 49-67
17. Castleden CM, Volans GN, Raymond K. The effects of ageing on drug absorption from the gut. Age Ageing 1977; 6: 138-43
18. Robertson DRC, Waller DG, Renwick AG, et al. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 25: 297-305
19. Veering BTH, Burm AGL, Souverijn JHM, et al. The effect of ace on serum concentration of albumin and αI-acid glycoprotein. Br J Clin Pharmacol 1990; 29: 201-6
20. Rowe J W, Andrew J, Tobin JD, et al. Age-adjusted standards for creatinine clearance. Ann Intern Med 1976; 84: 567-9
21. Woodhouse KW, James OFW. Hepatic drug metabolism and ageing. Br Med Bull 1990; 46: 22-35
22. George G, Wynne HA, Woodhouse KW. The association of age with the induction of drug metabolising enzymes in human monocytes. Age Ageing 1990; 19: 364-7
23. Leibowitz SF. Hypothalamic neuropeptide Y, galanin, and amines: concepts and coexistence in relation to feeding behavior. Ann N Y Acad Sci 1989; 575: 221-33
24. Wellman PJ, Davies BT. Reversal of the cirazoline-induced and phenylpropanolamine-induced anorexia by the alpha-1 receptor antagonist prazosin. Pharmacol Biochem Behav 1992; 42: 97-100
25. Schteingert DE. Phenylpropanolamine in the management of moderate obesity. In: Van Itallie TB, Simopoulos AP, editors. Obesity: new directions in assessment and management. Philadelphia: The Charles Press, 1995: 220-6
26. Leibowitz SF. Reciprocal hunger-regulating circuits involving alpha- and beta-adrenergic receptors located, respectively, in the ventromedial and lateral hypothalamus. Proc Natl Acad Sci U S A 1970; 67: 1063-70
27. Kucio C, Jonderko K, Piskorska D. Does yohimbine act as a slimming drug? Isr J Med Sci 1991; 27: 550-6
28. Scoville BA. Review of amphetamine-like drugs by the Food and Drug Administration: clinical data and value judgements. In: Obesity in perspective. Edited by DHEW Publ. No. NIH 75-708. Bethesda (MD): US Government Printing Office, 1974: 441-3
29. Ebenezer IS. Effects of the 5-HT1 agonist 8-OH-DPAT on food intake in food deprived rats. Neuroreport 1992; 3: 1019-22
30. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long-term dextrofenfluramine in obesity. Lancet 1989; 11: 1142-4
31. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-16
32. Weintraub M. Long term weight control (parts 1-7): the National Heart Lung and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992; 51: 581-641
33. National Task Force on the Prevention and Treatment of Obesity. Long term pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907-15
34. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-8
35. Poehlman ET, Arciero PJ, Goran MI. Endurance exercise in aging humans: effects of energy metabolism. In: Holloszy JO, editor. Exercise and sport science review. Baltimore (MD): Williams & Wilkins, 1994: 251-84
36. Mertz W. Chromium in human nutrition: a review. J Nutr 1993; 123: 626-33
37. McCarty MF. Homologous physiological effects of phenformin and chromium picolinate. Med Hypotheses 1993; 41: 316-24
38. McCarty MF. Anabolic effects of insulin on bone suggests a role for chromium picolinate in preservation of bone density. Med Hypotheses 1995; 45: 241-6
39. Evans GW. The effect of chromium picolinate on insulin controlled parameter in humans. Int J Biosoc Med Res 1989; 35: 273-80
40. Kaats GR, Fisher JA, Blum K. The effects of chromium picolinate supplementation on body composition in different age groups [abstract]. Age 1991; 14: 138
41. Hasten DL, Rome EP, Franks BD, et al. Effects of chromium picolinate on beginning weight training students. Int J Sport Nutr 1992; 2: 343-50
42. Clancy SP, Clarkson PM, DeCheke ME, et al. Effects of chromium picolinate supplementation on body composition, strength, and urinary chromium loss in football players. Int J Sport Nutr 1994; 4: 142-53
43. Trent LK, Thieding-Cancel D. Effects of chromium picolinate on body composition. J Sports Med Phys Fitness 1995; 35: 273-80
44. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? Metabolism 1992; 41: 1233-41
45. Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes 1993; 17 Suppl.: S41-3
46. Pasquali R, Casimirri F. Clinical aspects of ephedrine in the treatment of obesity. Int J Obes 1993; 17 Suppl.: S65-8
47. Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double-blind trial. Int J Obes 1992; 16: 269-77
48. Astrup A, Buemann B, Christensen NJ, et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism 1992; 41: 686-8
49. 3-adrenergic receptor. Science 1989; 245: 1118-21
50. 3-Adrenoceptor: an update. Eur J Endocrinol 1995; 132: 377-85
51. 3-adrenergic-receptor with NIDDM and body weight gain. Diabetologia 1996; 39: 349-52
52. 3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun 1995; 215: 555-60
53. 3-adrenergic receptor gene Trp64 Arg mutation is overrepresented in obese women. Diabetes 1996; 45: 1358-63
54. 3-adrenergic receptor gene. Diabetes 1996; 45: 1115-20
55. 3-adrenergic-receptor gene. N Engl J Med 1995; 333: 343-7
56. 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995; 333: 348-51
57. 3-adrenergic-receptor gene and response to treatment of obesity. Lancet 1995; 346: 1433-4
58. 3-adrenoceptor gene of doubtful significance for obesity and insulin resistance. Lancet 1996; 348: 698-9
59. 3-Adrenergic agonists. Drugs Fut 1993; 18: 529-49
60. 3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes 1996; 20: 191-9
61. 3-adrenoceptors. Br J Clin Pharmacol 1996; 42: 291-300
62. 3-agonist, on energy balance and brown and white adipose tissues in rats. Am J Physiol 1994; 266: R1371-82
63. Connacher AA, Bennet WM, Jung RT. Clinical studies with the β-adrenoceplor agonist BRL 26830A. Am J Clin Nutr 1992; 55 Suppl.: 258S-61S
64. Lovejoy JC, Greeson CS, Klemperer M, et al. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Int J Obes 1995; 19: 614-24
65. Hussain Y, Guzelham C, Odink J, et al. Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat. J Clin Pharmacol 1994; 34: 1121-5
66. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82-5
67. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of obesity: a multiple dose study. Int J Obes 1995; 19: 221-6
68. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes 1993; 17: 241-4
69. Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46: 405-10
70. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995; 35: 1103-8
71. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996; 36: 647-53
72. Ballor DL, Harvey-Berino JR, Ades PA, et al. Decrease in fat oxidation following a meal in weight-reduced individuals: a possible mechanism for weight recidivism. Metabolism 1996; 45: 174-8
73. Calles-Escandon J, Sobel B, Ballor D, et al. Amelioration of the inhibition of fibrinolysis in elderly obese subjects by moderate weight loss. Am J Clin Nutr 1996; 64: 7-11